Mistral Pharma Announces Positive Results From a Pilot PK Study on MIST-B04
03 Dicembre 2007 - 1:59PM
Marketwired
MONTREAL, QUEBEC ("Mistral") today announced positive results
from a first pilot pharmacokinetic (PK) study on a new
controlled-release product, MIST-B04. The results of this pilot
study clearly show that MIST-B04 presents a pharmacokinetic profile
leading to a once daily dosing schedule compared to the three times
daily immediate-release formulation presently on the market.
MIST-B04 is formulated using a new drug delivery platform named
TRIZERO(TM), which was developed internally by Mistral's scientists
and for which a patent application was filed in June 2007.
"We are very excited by these positive results on MIST-B04"
commented Bertrand Bolduc. "They show that our brand new
TRIZERO(TM) platform is performing very well in vivo and this opens
up many other opportunities for line-extension products for
MIST-B04" he added.
Mistral's MIST-B04 is a controlled-delivery branded product in
the rheumatology / inflammation field. According to Drug Topics,
sales for the branded product targeted by MIST-B04 were more than
US$ 200 M in the US in 2006.
About Mistral Pharma Inc.
Mistral Pharma Inc. is an innovative pharmaceutical company that
is active in the reformulation and the commercialization of
already-marketed drugs. Its branded drug delivery products,
MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive
results at their respective first pilot clinical trials. Mistral
also markets INSTILLAGEL� in Canada, a local anesthetic and
antiseptic combination product used for urology procedures. Mistral
has also in-licensed TAMALIS(TM) (Rupatadine) a new antihistamine
and INSTILLAQUILL�, a single use extension tube used in gynecology.
They should both be filed with Health Canada in 2008. Mistral
positions itself as a development and marketing partner for
pharmaceutical companies. More information is available on
Mistral's website at www.mistralpharma.com.
Forward-looking Statements
Except for historical information provided herein, this press
release may contain information and statements of a forward-looking
nature concerning the future performance of Mistral Pharma. These
statements are based on assumptions and uncertainties as well as on
Management's best possible evaluation of future events. Such
factors may include, without excluding other considerations,
fluctuations in quarterly results, evolution in customer demand for
Mistral Pharma's products, the impact of price pressures exerted by
competitors, results from clinical studies and regulatory approval
process as well as general market trends or economic changes. As a
result, readers are advised that actual results may differ from
expected results.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this press release.
Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA
President & Chief Executive Officer 514-421-1717 # 2224
bbolduc@mistralpharma.com Mistral Pharma Inc. Alain Provencher, CA,
CF Vice-president, Finance & Chief Financial Officer
514-421-1717 # 2222 aprovencher@mistralpharma.com
Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Set 2023 a Set 2024